Primary Renal Lymphoma: Long-Term Results of Two Patients Treated with a Chemotherapy + Rituximab Protocol | Zendy

Fernando VázquezAlonso | Zendy; Ignacio PucheSanz | Zendy; Cristina SánchezRamos | Zendy; José Francisco Flores-Martín | Zendy; Javier Vicente-Prados | Zendy; J.M. Cózar-Olmo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Primary Renal Lymphoma: Long-Term Results of Two Patients Treated with a Chemotherapy + Rituximab Protocol

Author(s) -

Fernando VázquezAlonso,

Ignacio PucheSanz,

Cristina SánchezRamos,

José Francisco Flores-Martín,

Javier Vicente-Prados,

J.M. Cózar-Olmo

Publication year - 2012

Publication title -

case reports in oncological medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.173

H-Index - 7

eISSN - 2090-6714

pISSN - 2090-6706

DOI - 10.1155/2012/726424

Subject(s) - rituximab , medicine , vincristine , cyclophosphamide , chop , prednisolone , regimen , chemotherapy , lymphoma , surgery , etiology , oncology

Primary renal lymphoma (PRL) is a rare disease of which the etiology and pathogenesis remain controversial, and there is currently no standard treatment for it. We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen. Both patients reached a complete response, and there is no evidence of recurrence after 4.5- and 5-year followup periods. Based on our experience and other recently published studies, we recommend the combination of CHOP + rituximab as the elective treatment for this disease. To our knowledge, this is the longest followup period with a complete response that has been reported with this modality of treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research